Addressing the oxamniquine in vitro-in vivo paradox to facilitate a new generation of anti-schistosome treatments

The antischistosomal drug oxamniquine, OXA, requires activation by a sulfotransferase within the parasitic worm to enable killing. Examination of the pharmacokinetic/pharmacodynamic (PK/PD) relationship for OXA identified an in vitro-in vivo paradox with the maximal clinical plasma concentrations fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Toth, Katalin, Alwan, Sevan, Khan, Susan, McHardy, Stanton F., LoVerde, Philip T., Cameron, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Regular article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929523/
https://www.ncbi.nlm.nih.gov/pubmed/36758271
http://dx.doi.org/10.1016/j.ijpddr.2023.01.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929523/
https://www.ncbi.nlm.nih.gov/pubmed/36758271
http://dx.doi.org/10.1016/j.ijpddr.2023.01.003

Ejemplares similares